1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: LYRICA (Pregabalin) Capsules

Trade Name: LYRICA
Chemical Family: Mixture
Intended Use: Pharmaceutical product

2. HAZARDS IDENTIFICATION

Appearance: Capsules varying in color depending on strength
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.

Additional Hazard Information:

Long Term: Animal studies indicate that this material may cause adverse effects on the fetus.
Known Clinical Effects: Adverse effects most commonly reported in clinical use include dizziness, blurred vision, weight gain, sleepiness (somnolence), inability to concentrate, swelling, dry mouth. Hypersensitivity reactions may also occur in susceptible individuals. Other less common effects include suicidal behavior.

EU Indication of danger: Harmful
Toxic to Reproduction: Category 3

EU Hazard Symbols:

EU Risk Phrases: R63 - Possible risk of harm to the unborn child.
2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin</td>
<td>148553-50-8</td>
<td>Not Listed</td>
<td>Repr. Cat. 3;R63</td>
<td>&lt;= 75</td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hard gelatin capsules</td>
<td>MIXTURE</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Use appropriate ventilation. Avoid generating airborne dust. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Pregabalin
Pfizer OEL TWA-8 Hr: 500µg/m³

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA) 2 mg/m³
Australia TWA 2.5 mg/m³
Austria OEL - MAKs 2 mg/m³
Belgium OEL - TWA 2 mg/m³
Bulgaria OEL - TWA 1.0 fiber/cm³
6.0 mg/m³
3.0 mg/m³
Czech Republic OEL - TWA 2.0 mg/m³
10 mg/m³
Denmark OEL - TWA 0.3 fiber/cm³
Finland OEL - TWA 0.5 fiber/cm³
5 mg/m³
Greece OEL - TWA 10 mg/m³
2 mg/m³
Hungary OEL - TWA 2 mg/m³
Ireland OEL - TWAs 10 mg/m³
0.8 mg/m³
Lithuania OEL - TWA 2 mg/m³
1 mg/m³
Netherlands OEL - TWA 0.25 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Environmental Exposure Controls:** Refer to specific Member State legislation for requirements under Community environmental legislation.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Capsule</th>
<th>Color:</th>
<th>Various</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

Polymerization: Will not occur
10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mist) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Talc (non-asbestiform)
Rat Oral LD50 > 1600 mg/kg

Pregabalin
Rat IV LD50 > 300 mg/kg
Mouse Oral LD50 > 5000 mg/kg
Rat Oral LD50 > 5000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Pregabalin
Skin Sensitization - LLNA Rat Negative
Skin Sensitization - Beuhler Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pregabalin
13 Week(s) Rat Oral 50 mg/kg/day NOAEL Central nervous system, Male reproductive system
4 Week(s) Rat Oral 500 mg/kg/day LOAEL Central Nervous System, Male reproductive system
4 Week(s) Monkey Oral 100 mg/kg/day NOAEL Central Nervous System
52 Week(s) Rat Oral 50 mg/kg/day LOAEL Blood forming organs

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pregabalin
Peri-/Postnatal Development Rat Oral 100 mg/kg/day NOAEL Developmental toxicity, Fertility
Fertility & Early Embryonic Development - Males Rat Oral 250 mg/kg/day NOAEL No effects at maximum dose
Fertility & Embryonic Development-Females Rat Oral 1250 mg/kg/day NOAEL Negative
Embryo / Fetal Development Rat Oral 500 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 500 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pregabalin
Bacterial Mutagenicity (Ames) Bacteria Negative
In Vivo Unscheduled DNA Synthesis Rat Negative
In Vivo Micronucleus Mouse Negative
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pregabalin
104 Week(s) Mouse Oral 1000 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Rat Oral 450 mg/kg/day NOAEL Not carcinogenic
104 Week(s) Mouse Oral 200 mg/kg/day NOAEL Malignant tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Talc (non-asbestiform)
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Pregabalin
Daphnia magna (Water Flea) EC50 48 Hours > 1000 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 1000 mg/L
Green algae OECD EbC50 72 Hours > 300 mg/L
Green Algae OECD ErC50 72 Hours > 300 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Pregabalin
Aspergillus niger (Fungus) OECD MIC > 1000 mg/L
Trichoderma viride (Fungus) OECD MIC > 1000 mg/L
Clostridium perfringens (Bacterium) OECD MIC > 997 mg/L
Bacillus subtilis (Bacterium) OECD MIC >1000 mg/L
Nostoc sp. (Freshwater Cyanobacteria) OECD MIC > 1000 mg/L

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful
Toxic to Reproduction: Category 3

EU Risk Phrases: R63 - Possible risk of harm to the unborn child.

EU Safety Phrases: S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
WARNING
Suspected of damaging the unborn child.

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Pregabalin
U.S. Drug Enforcement Administration: Schedule V Controlled Substance
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

Talc (non-asbestiform)
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List 238-877-9

Corn Starch
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 232-679-6

Lactose NF, monohydrate
Australia (AICS): Present

Additional Information: U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule V
16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 9 - Physical and Chemical Properties. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 15 - Regulatory Information.


Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet